Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

Hemasphere · 2020 · PMC7587416 · PMID 33134869

Europe PMC DOI

hedged sentences

0.1092

closest p · 2.2× alpha

0.1092

boldest claim

The sentences

showed a trendp = 0.1092not close (p > 0.1)

Results for CHR with improved disease burden showed a trend towards higher rates in the ropeginterferon arm vs control (55.1% vs 37.1%, respectively; RR: 1.49 [95% CI: 0.91 to 2.43], p = 0.1092 in patients < 60 years; 43.5% vs 36.1%; RR: 1.22 [95% CI: 0.70 to 2.11], p = 0.4774 in those ≥60 years; Fig. 1 B i ; Supplementary Digital Content, Table 7).

also in 53,322 other papers

a positive trendno p-value reported

Moreover, the safety analysis in patients ≥60 years showed a positive trend regarding fewer and less serious treatment-related AEs compared to HU.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.